

# Optical tissue clearing in combination with perfusion and immunofluorescence for placental vascular imaging

Maira Carrillo, PhD<sup>a</sup>, Marcel Chuecos, BS<sup>a</sup>, Kushal Gandhi, PhD<sup>a</sup>, Andrey Bednov, PhD<sup>a,b</sup>, David Lee Moore, MD<sup>a</sup>, James Maher, MD<sup>a,b</sup>, Gary Ventolini, MD<sup>a</sup>, Guangchen Ji, PhD<sup>c</sup>, Natalia Schlabritz-Loutsevitch, MD, PhD<sup>a,b,c,\*</sup>

## Abstract

Imaging of placental tissues is a difficult task, because of specific for this organ complex multicellular and 3D tissue structure. The tissue clearing systems (X-CLARITY) system is a valuable tool for the examining the expression of molecular pathways in whole tissues and organs, originally developed for brain imaging.

In the present report, we utilized this technology for the examination of placental vasculature and protein expression in perfused human placental tissue.

The placental tissue was sufficiently cleared with preservation of endothelial staining and fluorescent markers, allowing visualization using confocal microscopy. The CLARITY method and X-CLARITY system is a valuable tool in placental imaging.

**Abbreviations:** BODIPY-C12 = 4,4-difluoro-5-methyl-4-bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid, 3D = 3-dimensional, Dil = 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate, FITC = fluorescein isothiocyanate, PBS = phosphate-buffered saline, X-CLARITY = tissue clearing systems.

**Keywords:** 3D, image clearing, perfusion, placenta, vasculature

## 1. Introduction

The placenta is poorly understood, but is one of the most important organs of the body,<sup>[1]</sup> since it supports fetal growth. In turn, fetal growth is closely related to the vascular architecture of placenta.<sup>[2]</sup> Pathology of placental vascular development is associated with abnormal fetal development.<sup>[3,4]</sup> The preservation of villous architecture is essential for evaluation of vascular composition since maternal and fetal pressure are factors, which estimate placental vascular-syntial membrane morphology.<sup>[5]</sup> The complex placental structure represents significant burden in evaluation of placental vascular tree.<sup>[6]</sup> The method of “clearing” a whole mouse

brain by transforming it into a porous hydrogel-hybridized form that retains tissue characteristics such as receptor location and other natural structures was originally developed by Deisseroth group<sup>[7]</sup> and was applied to human placenta previously.<sup>[8]</sup> The tissue clearing systems (X-CLARITY, Logos Biosystems, VA) is capable of clearing tissue in half the time of the original method.<sup>[7,9–11]</sup>

Here, we applied this method to perfused human placental tissue after vascular staining, allowing for the examination of the intact vascular architecture and evaluation of the spatial expression of lipids and proteins.

## 2. Materials and methods

### 2.1. Placental collection and general protocol

Four placentas were collected within 1 to 2 minutes after delivery (this study was approved by TTUHSC Institutional Review Board, protocol #L15–108) and an isolated placental cotyledon was cannulated within 5 to 7 minutes after collection. Placental perfusion was performed in accordance with the *ex vivo* placental perfusion protocol.<sup>[6]</sup> Details of the tissue processing are presented in Table 1.

### 2.2. Fluorescent markers used in placental perfusion

The fetal and maternal perfusion closed systems were established and perfusion was performed for at least 90 minutes. 4,4-Difluoro-5-methyl-4-bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid (BODIPY-C12, Cat. No. D3823, ThermoFisher Scientific; Waltham, MA) was added to the maternal side at the concentration 2  $\mu$ M according to the previously described protocol.<sup>[12]</sup> Fluorescein isothiocyanate (FITC)-conjugated dextran (Cat No. FD70S, Sigma–Aldrich, St Louis, MO) was added to fetal buffer at the working concentration of 200  $\mu$ g/mL, perfusion was performed during 90 to 120 minutes.<sup>[13]</sup>

Editor: Giuseppe Lucarelli.

Dr. C. Salafia, Institute for Basic Research, Carolyn.salafia@gmail.com

Dr. Lopa Leach, University of Nottingham, Lopa.leach@nottingham.ac.uk

The authors have no funding and conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

<sup>a</sup> Department of Obstetrics and Gynecology, School of Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, <sup>b</sup> University of Texas of the Permian Basin, <sup>c</sup> Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

\* Correspondence: Natalia Schlabritz-Loutsevitch, Department of Obstetrics and Gynecology, School of Medicine, Texas Tech University Health Sciences Center, 701W. 5th Street, Odessa, TX 79763, USA  
(e-mail: natalia.schlubritz-loutsevitch@ttuhsc.edu).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:39(e12392)

Received: 4 May 2018 / Accepted: 23 August 2018

<http://dx.doi.org/10.1097/MD.00000000000012392>

**Table 1****Details of experimental procedures.**

Placental ID	Perfusion protocol/fetal flow rate	Endothelial staining Dil	FITC – conjugated Dextran		Time in the fixative, d	Tissue embedding	Immunohistochemistry after CLARITY treatment	Images (presented on Fig. 1)
			BODIPY-12	in fetal circuit				
1	High fetal flow rate (12 mL/min)	Yes	No	No	20	4% Agarose	No	D
2	Initial perfusion	Yes	No	No	At least 7 days	4% Agarose	No	F
3	Fatty acid transfer (6 mL/min)	Yes	Yes	No	1	4% Agarose	Yes	E, G–J
4	High fetal flow rate (12 mL/min)	Yes	No	Yes	7	X-CLARITY mounting medium	Yes	K, L

BODIPY-C12 = 4,4-difluoro-5-methyl-4-bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid, Dil = 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyaninperchlorate, FITC = fluorescein isothiocyanate, X-CLARITY = tissue clearing systems.

### 2.3. Endothelial staining

At the end of perfusion, each cotyledon was infused with 12 mL of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyaninperchlorate (DiI, Cat No. 42364, Sigma–Aldrich; St. Louis, MO) at the rate 6 mL/minutes, and subsequently with 12 mL of 4% paraformaldehyde at the same flow rate, using modified published protocol.<sup>[14]</sup> Subsequently a portion of the cotyledon was fixed for 1 to 7 days in 4% paraformaldehyde (4.0°C).

### 2.4. Tissue embedding

All but one of the placental specimens were embedded in 4% agarose and sections with 300 to 400 µm thickness were cut with vibratome (The Vibratome Co, St. Louis, MO).

### 2.5. Tissue clearing using the X-CLARITY system

The tissue was removed from the fixative, rinsed with 1× phosphate-buffered saline (PBS) several times and then incubated in 1× PBS at 4.0°C for 24 hours. Afterward the tissue was immersed in the X-CLARITY polymerization initiator solution and processed according to manufacturer's instructions. Briefly, the samples were incubated for 24 hours at 4.0°C, polymerized for 3 hours at a vacuum (kPa) of –85, and a temperature of 37.0°C, shaken for 1 minute and rinsed 1× PBS. Subsequently samples were processed in the electrophoretic tissue clearing (ETC) solution for 20 hours (checked after 2 hours) at a current of 1.1 A, temperature of 37.0°C and pump speed of 30 rpm. Tissue was stored at 4.0°C for 1 week. The primary antibody Perilipin 2 (Cat No. ab181452, Abcam; New York, NY) was prepared at a dilution of 1:100 in antibody dilution solution (1× PBS, 6% bovine serum albumin, 0.1% Triton X-100 and 0.01% sodium azide) and incubated at 37.0°C with specimens for 5 days. The secondary antibody, Alexa 488 (Cat No. A-11029, Thermo-Fisher; Austin, TX), was prepared at a 1:100 dilution in antibody dilution solution (same as above) and the tissue was incubated in this antibody solution for an additional 5 days. Subsequently, samples were stored in 1× PBS at 4.0°C. Before taking images, the samples were placed in X-CLARITY mounting solution for 1 hour. All fluorescent images were taken using the T1-E microscope with A1 confocal and STochastic Optical Reconstruction Microscopy super-resolution modules (Nikon Instruments Melville, NY).

### 2.6. Image processing


Images were processed using Imaris, 9.0.1 software (Bitplane, Oxford Instruments, concord, MA) and Image-Pro Premier 9.1 software (Hamamatsu, Japan).

## 3. Results

The placental tissue was sufficiently cleared and the refractive index (RI) matched well with the X-CLARITY mounting solution, providing maximal clarity (Fig. 1A–C). Fetal vascular tree was visualized after cleaning of the specimen with the preservation of the endothelial staining (Fig. 1H), when compared to the conventional method (Fig. 1D–F) (see video 1, Supplemental Video, <http://links.lww.com/MD/C521> [Video 1: Dil staining (red), conventional method]). The endothelial staining was fading, when specimen was kept in fixative for 7 days prior to clearing (Fig. 1F (see video 2, Supplemental Video, <http://links.lww.com/MD/C522>) [Video 2: Dil staining (red), overlay image with auto fluorescence (green), conventional method, 7 days fixation]), L (see video 3, Supplemental Video, <http://links.lww.com/MD/C523>) [Video 3: Placental tissue perfused with Dil (red) and FITC-conjugated dextran, tissue clearing, 7 days fixation]). The BODIPY-C12 was localized on syncytiotrophoblast (ST) and endothelial cells (Fig. 1E), image clearing resulted in absence of ST staining (Fig. 1G–J) (see video 4, Supplemental Video, <http://links.lww.com/MD/C524> [Video 4: Overlay of Dil (red) and perilipin/ BODIPY-C12 staining (green), tissue clearing]). Subsequent to clearing, staining with perilipin-2 demonstrated peri- and endovascular localization of the lipid-related molecules (Fig. 1I (see video 4, Supplemental Video, <http://links.lww.com/MD/C524> [Video 4: Overlay of Dil (red) and perilipin/ BODIPY-C12 staining (green), tissue clearing]), J). Perfusion of fetal side with FITC-conjugated dextran enhanced green fluorescence background staining (Fig. 1K (see video 5, Supplemental Video, <http://links.lww.com/MD/C525> [Video 5: FITC-conjugated dextran staining after fetal perfusion (green fluorescence), tissue clearing]), L (see video 3, Supplemental Video, <http://links.lww.com/MD/C523>) [Video 3: Placental tissue perfused with Dil (red) and FITC-conjugated dextran, tissue clearing, 7 days fixation])). In the later fetomaternal buffer transfer was above acceptable 3 mL/hour, when fetal flow rate was increased to 12 mL/minute.

## 4. Discussion

The ability to examine intact placental vasculature in the human placenta is a difficult task, hampered by the complex structure of this organ.<sup>[15]</sup> Many methods for characterization and quantification of placental vasculature have been published including vascular casting,<sup>[16,17]</sup> and 3-dimensional (3D) computational modeling.<sup>[18]</sup> However, thus far, none of the methods have been able to provide an undisturbed visualization of the placental vasculature and expression of functional lipids and proteins in placental endothelial cells in 3D images. Tissue clearing has been used for visualization of placenta in rodents<sup>[11]</sup> and for the



**Figure 1.** Imaging of placental tissue. Upper panel: (A–C) tissues before and after clearing with CLARITY system. Upper panel: (A) tissue before clearing; (B) tissue after clearing, before placing in mounting medium; and (C) cleared tissue placed in mounting medium. Second panel: (D–F) tissues were not cleared. (D) Dil staining, (E) BODIPY-C12 perfusion and Dil staining, and (F) Dil staining, overlay image with auto fluorescence. Third panel: (G–I) tissue cleared with CLARITY system. (G) Green fluorescence: BODIPY-C12 perfusion and Perilipin-2 staining. (H) Red fluorescence: Dil staining, (I) overlay of Dil and perilipin/BODIPY-C12 staining. Low panel: (J) overlay of Dil and perilipin/BODIPY-C12 staining, tissue cleaning; (K) green fluorescence: Perilipin-2 staining in the placental tissue perfused with Dil and FITC dextran, (L) controls (omission of secondary antibody green fluorescence: Perilipin-2 staining in the placental tissue perfused with Dil and FITC dextran). Notice: In all images: red fluorescence is Dil (vascular endothelial staining) and green fluorescence, is BODIPY-C12, Cat. No. D3823, ThermoFisher Scientific; Waltham, MA), perilipin-2 after tissue clearing or FITC conjugated dextran. Image A was taken using Nikon D3200, AF-S Nikon 18 to 55 mm lens, image C using a Canon 5D Mark II with a 100mm macro lens camera on a copy stand with trans-illumination. Images D–I and K, L were taken with a 10× objective on a Nikon T1-E microscope with A1 confocal and STORM super-resolution modules. Images E, J, H, I, and J were adjusted using Imaris, 9.0.1 software; images D, F, K, and L were adjusted using Image-Pro Premier 9.1 software. Tissue in D–J were mounted in agarose gel and sliced to 300 μm with vibratome, K, L whole tissue in CLARITY mounting medium in a petri dish each ~5 mm. Scale bars 150 μm in all images except J with scale bar 40 μm. BODIPY-C12 = 4,4-difluoro-5-methyl-4-bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid, Dil = 1,1'-dioctadecyl-3,3',3'-tetramethylindocarbocyanin perchlorate, FITC = fluorescein isothiocyanate, X-CLARITY = tissue clearing systems.

evaluation of 3D structure of fetal membranes<sup>[19]</sup>/placental tissue in humans.<sup>[8]</sup> The novelty of the presented method is that the endothelial staining was performed prior to tissue clearing under physiological conditions (controlled temperature, flow rate), thus preserving the vascular architecture. By additional perfusion with BODIPY-C12 and FITC-conjugated Dextran prior to clearing and perilipin-2 immuno-staining after clearing, we were able to stain the placental vasculature as well as localize areas of lipid metabolism. Cleared tissue may also reduce the amount of “manual cleaning” needed in computational modeling when interpreting images.<sup>[18]</sup> The limitation of the technique at the present stage of development is the absence of the visualization of intravillous capillary loops, which are detectable with the other techniques.<sup>[20]</sup> Nevertheless, the application of this technology allows precise evaluation of 3D functional morphology of placental blood barrier and its transport capacities, which is an important question in the light of the development of nanotechnologies and understanding of role of exosomes in fetal development.<sup>[21,22]</sup>

### Acknowledgments

Confocal images were generated in the Image Analysis Core Facility supported in part by TTUHSC. Authors thank the director of the Core facility Dr. Petar Grozdanov for the support and expertise with confocal images. Authors also thank the help of Dr. Senthil Saravanamuthu with the X-CLARITY system; Dr. Takaki Kiritoshi (TTUHSC) with tissue preparations; and specially the TTUHSC Clinical Research Institute for help with placenta collection. Authors grateful Mr. Neal Hinkle (TTUHSC) for his help with medical photography.

### Author contributions

**Conceptualization:** Natalia Schlabritz-Loutsevitch.  
**Data curation:** Marcel Chuecos, Natalia Schlabritz-Loutsevitch.  
**Formal analysis:** Marcel Chuecos, Natalia Schlabritz-Loutsevitch.  
**Funding acquisition:** Natalia Schlabritz-Loutsevitch.  
**Investigation:** Andrey Bednov, Maira Carrillo, Marcel Chuecos, Kushal Gandhi, Natalia Schlabritz-Loutsevitch, Guanghen Ji.  
**Methodology:** Maira Carrillo, Marcel Chuecos, Kushal Gandhi, Andrey Bednov, Guanghen Ji, Natalia Schlabritz-Loutsevitch.  
**Project administration:** Andrey Bednov, Natalia Schlabritz-Loutsevitch.  
**Resources:** David Lee Moore, James Maher, Gary Ventolini, Guanghen Ji, Natalia Schlabritz-Loutsevitch.  
**Software:** Marcel Chuecos, Natalia Schlabritz-Loutsevitch.  
**Supervision:** Natalia Schlabritz-Loutsevitch.  
**Validation:** Natalia Schlabritz-Loutsevitch.  
**Visualization:** Marcel Chuecos.  
**Writing – original draft:** Maira Carrillo, Marcel Chuecos, Natalia Schlabritz-Loutsevitch.

**Writing – review & editing:** Marcel Chuecos, Kushal Gandhi, David Lee Moore, James Maher, Natalia Schlabritz-Loutsevitch.

### References

- [1] Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. *Philos Trans R Soc Lond B Biol Sci* 2015;370:20140066.
- [2] Kingdom J, Huppertz B, Seaward G, et al. Development of the placental villous tree and its consequences for fetal growth. *Eur J Obstetr Gynecol Reprod Biol* 2000;92:35–43.
- [3] Su EJ. Role of the fetoplacental endothelium in fetal growth restriction with abnormal umbilical artery Doppler velocimetry. *Am J Obstet Gynecol* 2015;213(4 Suppl):S123–30.
- [4] Leach L. Placental vascular dysfunction in diabetic pregnancies: intimations of fetal cardiovascular disease? *Microcirculation (NY)* 2011;18:263–9.
- [5] Feneley MR, Burton GJ. Villous composition and membrane thickness in the human placenta at term: a stereological study using unbiased estimators and optimal fixation techniques. *Placenta* 1991;12:131–42.
- [6] Gude NM, Roberts CT, Kalionis B, et al. Growth and function of the normal human placenta. *Thromb Res* 2004;114:397–407.
- [7] Chung K, Wallace J, Kim SY, et al. Structural and molecular interrogation of intact biological systems. *Nature* 2013;497:332–7.
- [8] Merz G, Schwenk V, Shah RG, et al. Clarification and 3-D visualization of immunolabeled human placenta villi. *Placenta* 2017;53:36–9.
- [9] Cronan MR, Rosenberg AF, Oehlers SH, et al. CLARITY and PACT-based imaging of adult zebrafish and mouse for whole-animal analysis of infections. *Dis Model Mech* 2015;8:1643–50.
- [10] Palmer WM, Martin AP, Flynn JR, et al. PEA-CLARITY: 3D molecular imaging of whole plant organs. *Sci Rep* 2015;5:13492.
- [11] Kagami K, Shinmyo Y, Ono M, et al. Three-dimensional visualization of intrauterine conceptus through the uterine wall by tissue clearing method. *Sci Rep* 2017;7:5964.
- [12] Kolahi K, Louey S, Varlamov O, et al. Real-time tracking of BODIPY-C12 long-chain fatty acid in human term placenta reveals unique lipid dynamics in cytotrophoblast cells. *PLoS One* 2016;11:e0153522.
- [13] Mathiesen L, Mose T, Morck TJ, et al. Quality assessment of a placental perfusion protocol. *Reprod Toxicol (Elmsford, NY)* 2010;30:138–46.
- [14] Li Y, Song Y, Zhao L, et al. Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. *Nat Protoc* 2008;3:1703–8.
- [15] Clark AR, Lin M, Tawhai M, et al. Multiscale modelling of the fetoplacental vasculature. *Interface Focus* 2015;5:20140078.
- [16] Junaid TO, Bradley RS, Lewis RM, et al. Whole organ vascular casting and microCT examination of the human placental vascular tree reveals novel alterations associated with pregnancy disease. *Sci Rep* 2017;7:4144.
- [17] Pratt R, Hutchinson JC, Melbourne A, et al. Imaging the human placental microcirculation with micro-focus computed tomography: optimisation of tissue preparation and image acquisition. *Placenta* 2017;60:36–9.
- [18] Plitman Mayo R, Charnock-Jones DS, Burton GJ, et al. Three-dimensional modeling of human placental terminal villi. *Placenta* 2016;43:54–60.
- [19] Richardson L, Vargas G, Brown T, et al. Redefining 3 dimensional placental membrane microarchitecture using multiphoton microscopy and optical clearing. *Placenta* 2017;53:66–75.
- [20] Jirkovska M, Kucera T, Kalab J, et al. The branching pattern of villous capillaries and structural changes of placental terminal villi in type 1 diabetes mellitus. *Placenta* 2012;33:343–51.
- [21] Muller EK, Grafe C, Wiekhorst F, et al. Magnetic nanoparticles interact and pass an in vitro co-culture blood-placenta barrier model. *Nanomaterials (Basel, Switzerland)* 2018;8: pii: E108.
- [22] Shi R, Zhao L, Cai W, et al. Maternal exosomes in diabetes contribute to the cardiac development deficiency. *Biochem Biophys Res Commun* 2017;483:602–8.